Protalix BioTherapeutics

Company Overview

Snapshot

Founded in January 1994, Protalix BioTherapeutics operates with 51–200 employees. The company has raised over $159.9 million across 11 funding rounds from 5 investors. In February 2021, Protalix BioTherapeutics completed a public offering, raising approximately $40 million.

Business overview

Protalix BioTherapeutics is a biopharmaceutical company specializing in the development, production, and commercialization of recombinant therapeutic proteins. Leveraging its proprietary ProCellEx plant-cell-based protein expression system, the company aims to create clinically superior versions of therapeutic proteins for established pharmaceutical markets. Its product pipeline includes treatments like Elelyso (taliglucerase alfa for injection), which received FDA approval in May 2012, and other candidates such as PRX-102 and PRX-115. Protalix BioTherapeutics operates within the Health Tech & Life Sciences sector, focusing on Pharma & Medical Biotechnology, specifically Drugs Discovery & Development, and serves the pharmaceutical industry.

Strategic signal

In September 2025, Protalix BioTherapeutics is scheduled to present at the H.C. Wainwright 27th Annual Global Investment Conference, signaling ongoing engagement with the investment community and a continued focus on communicating its strategic direction and pipeline progress. This consistent presence at key investor events indicates the company's commitment to maintaining investor confidence and attracting further capital, despite recent regulatory setbacks concerning Elfabrio's dosing regimen.

Company Intelligence Q&A

What is Protalix BioTherapeutics' primary focus?

Protalix BioTherapeutics focuses on the development, production, and commercialization of recombinant therapeutic proteins using its proprietary ProCellEx plant-cell-based protein expression system.

When did Protalix BioTherapeutics complete its most recent public offering?

In February 2021, Protalix BioTherapeutics completed a public offering on AMEX, raising $40M.

What was a significant partnership for Protalix BioTherapeutics regarding its Gaucher drug?

In October 2015, Protalix BioTherapeutics licensed its drug product, Elelyso (taliglucerase alfa for injection), to Pfizer, which had gained FDA approval in May 2012.

What was a recent strategic financial move by Protalix BioTherapeutics?

In September 2024, Protalix BioTherapeutics announced the repayment of outstanding senior secured convertible promissory notes.

What is the status of Protalix BioTherapeutics' upcoming investor engagements?

Protalix BioTherapeutics is scheduled to present at the H.C. Wainwright 27th Annual Global Investment Conference in September 2025, and at the Investor Summit Virtual in September 2025.